{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"Patients receiving the combination of oral 5-azacitidine and romidepsin and experiencing grades 1-4 toxicities will be tallied based on events observed and assessed by a qualified investigator. This Outcome Measure is specifically for Phase 1 of the study.","groups":[{"description":"Phase I is to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of the combinations of oral 5-azacitidine and romidepsin in patients with lymphoma. The safety and toxicity of this combination will be evaluated throughout the entire study.","id":"OG000","title":"Phase I"}],"paramType":"NUMBER","populationDescription":"This Outcome Measure is specific for Phase 1 of the study. This Outcome Measure was NOT applied to Phase 2, therefore data was only collected and reported for Phase 1. Results were not collected per dose level and thus cannot be reported per dose level.\n\n26 participants received the study interventions in Phase 1.","reportingStatus":"POSTED","timeFrame":"Up to 1.5 years","title":"Percentage of Patients Who Experienced Significant Toxicities in Phase 1","type":"PRIMARY","unitOfMeasure":"percentage of participants"}